Cognixion Launches Home Study of Non-Invasive BCI for ALS
The NIH-funded CHOICE study puts a brain-reading headset in 30 homes for 12 weeks and measures preference and use, not efficacy.
Edited and fact-checked by Stephen Sprague
Cognixion's CHOICE study will test a non-invasive BCI headset against eye tracking in 30 ALS patients' homes.
Thirty Americans with ALS will spend 12 weeks at home comparing eye tracking against a headset that reads brain signals.
Cognixion announced the CHOICE study on November 5, 2026, an NIH-funded home study enrolling 30 adults with ALS to compare their existing eye-tracking devices against head-worn and screen-based versions of its non-invasive brain-computer interface over roughly 12 weeks.
The study is funded by the National Institute on Deafness and Other Communication Disorders, part of the National Institutes of Health, under award R44DC023888, with $1,258,551 for the first budget year, and is registered as NCT07871071. Cognixion ONE pairs the non-invasive headset, which reads brain signals without surgery, with an AI-assisted communication app. Participants rotate through three options: the eye tracker they already use, the head-worn device and a screen-based version.
The scope deserves stating plainly, because the company states it plainly: CHOICE measures preference and use at home, not a clinical efficacy endpoint, and the announcement gives no start date for enrollment. For assistive communication, that is arguably the right first question. A device people with ALS will actually wear and keep using beats a faster device abandoned in a drawer, and a 12-week home comparison against the eye tracker already on the desk is how that answer gets measured instead of asserted.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.